LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.68 -1.18

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.6600000000000001

Max

1.78

Põhinäitajad
By Trading Economics
Sissetulek	-2.8M -16M
Müük	-8.7M 5.5M
Kasumimarginaal	-282.723
Töötajad	103
EBITDA	-4.2M -15M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+122.67% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	60M 712M
Eelmine avamishind	2.86
Eelmine sulgemishind	1.68

Uudiste sentiment

By Acuity

34%

66%

89 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. märts 2026, 19:08 UTC

Uudisväärsed sündmused

TotalEnergies Shutting Production in Qatar, Iraq Amid Fighting in Middle East

13. märts 2026, 18:48 UTC

Tulu

Suurimad hinnamuutused turgudel

Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss

13. märts 2026, 17:10 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

13. märts 2026, 17:10 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Central Bank Decisions -2-

13. märts 2026, 16:47 UTC

Uudisväärsed sündmused

The Week in Oil: Hormuz Crisis Pushes Brent Above $100

13. märts 2026, 22:27 UTC

Market Talk

Uudisväärsed sündmused

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

13. märts 2026, 22:13 UTC

Market Talk

Uudisväärsed sündmused

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

13. märts 2026, 22:04 UTC

Market Talk

Uudisväärsed sündmused

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

13. märts 2026, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

13. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

13. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

13. märts 2026, 20:02 UTC

Market Talk

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

13. märts 2026, 19:50 UTC

Market Talk

Uudisväärsed sündmused

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

13. märts 2026, 19:35 UTC

Uudisväärsed sündmused

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

13. märts 2026, 19:00 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

13. märts 2026, 18:49 UTC

Uudisväärsed sündmused

The Iran War Could Upend AI. Here's How. -- Barrons.com

13. märts 2026, 18:24 UTC

Uudisväärsed sündmused

Impact of Middle East Conflict on TotalEnergies Activities

13. märts 2026, 18:00 UTC

Uudisväärsed sündmused

Is War Good For the Economy? -- WSJ

13. märts 2026, 17:23 UTC

Market Talk

U.S. Oil Rig Count Rises by 1 to 412 -- Market Talk

13. märts 2026, 16:46 UTC

Market Talk

Uudisväärsed sündmused

European Indexes End Week Lower as Oil Takes Driving Seat -- Market Talk

13. märts 2026, 16:38 UTC

Uudisväärsed sündmused

Higher Oil Prices Could Bring a Global Economic Shock. This Is the Number to Watch. -- Barrons.com

13. märts 2026, 16:34 UTC

Omandamised, ülevõtmised, äriostud

EQT Says It Received Around CHF21 Bln in Total From Galderma Share Sales

13. märts 2026, 16:33 UTC

Omandamised, ülevõtmised, äriostud

EQT Receives Proceeds of Around CHF1.3B From Sell-Down

13. märts 2026, 16:32 UTC

Omandamised, ülevõtmised, äriostud

EQT Completes Exit From Galderma

13. märts 2026, 16:20 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

13. märts 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

13. märts 2026, 16:15 UTC

Uudisväärsed sündmused

Why Exxon and Energy Stocks Finally Started to Rise This Week as the Iran War Escalated -- Barrons.com

13. märts 2026, 16:11 UTC

Market Talk

Carney Tries to Put Dismal Canada Jobs Data in Context -- Market Talk

13. märts 2026, 16:00 UTC

Uudisväärsed sündmused

Here's Where the U.S. Economy Is Most Vulnerable to Iran War -- WSJ

13. märts 2026, 15:48 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Turn Higher as Supply Worries Remain -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

122.67% tõus

12 kuu keskmine prognoos

Keskmine 3.83 USD 122.67%

Kõrge 6 USD

Madal 1 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

89 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.